Skip to main content
European Commission logo print header

Normothermic Perfusion Device for Renal and Hepatic Preservation and Viability Assessment

Project description

Medical device for preserving organ transplants

Organ transplantation is a life-saving procedure for many people facing terminal diseases associated with end-stage organ failure. However, there are many impediments to the success of the procedure including organ preservation during transport. Conventionally, organs are preserved under cold conditions, but this is not optimal for all types of grafts. To address this medical need, the EU-funded NORMOPERF project proposes to develop an innovative medical device that can preserve organ grafts under physiological conditions including temperature using perfusion. The device is expected to improve the logistics of transplantation as well as the quality of organs with obvious benefits for the outcome of the procedure.

Objective

EBERS is a leading company in the field of bioreactors and cell culture systems, with a wide international presence in Europe, USA, Australia, and Asia. In the NORMOPERF project we go a step further by targeting the organ transplantation field by bringing to the healthcare market a new portable device for extracorporeal organ preservation based on a patented technology (P201730030).
Organ transplantation is in many cases the only effective therapy for end-stage organ failure. However, it is estimated that only 10% of the global organ needs are covered.
Traditionally, only organs obtained in optimal conditions have been considered for transplantation. However, organ lack is leading to the increased use of suboptimal grafts (e.g. non-heart beating donors), which poses new challenges. The most important hurdle preventing the clinical use of suboptimal organs is the limitation of static cold preservation (SCP). SCP is well suited for optimal grafts, but not for suboptimal ones since (i) it allows short preservation times (2-20 h), (ii) it does not provide information about the organ viability and (iii) it additionally damages the organ due to ischemia-reperfusion.
The solution proposed by EBERS is a new portable medical device based on normothermic perfusion, capable of maintaining human organs in a viable state for sustained periods under physiological conditions. The NORMOPERF project will offer the clinical community a new device for organ preservation that will contribute to increasing the number of organs available for transplantation by making possible the clinical use of a significant part of the suboptimal organs that are currently not even considered for transplantation. Thus, the use of our technology will allow increasing x2-3 the current transplant rates in the short term.
According to our conservative estimations, the €2.57 Mill required for this project will mean €21.3M cumulative EBITDA in 5-years, representing a ROI of 723%.

Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-2-2016-2017

Coordinator

EBERS MEDICAL TECHNOLOGY SL
Net EU contribution
€ 2 570 850,00
Address
Avenida de madrid 117 5 a
50010 Zaragoza
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Noreste Aragón Zaragoza
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 570 850,00